{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:34:12Z","timestamp":1791477252586,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41393-019-0411-0","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T13:03:04Z","timestamp":1578488584000},"page":"675-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury"],"prefix":"10.1038","volume":"58","author":[{"given":"Katrine P.","family":"Hebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Klarskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Bagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fin","family":"Biering-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Elmelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"411_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ucl.2017.04.003","volume":"44","author":"U Nseyo","year":"2017","unstructured":"Nseyo U, Santiago-lastra Y. Long-term complications of the neurogenic bladder. Urol Clin North Am. 2017;44:355\u201366.","journal-title":"Urol Clin North Am"},{"key":"411_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ucl.2010.07.002","volume":"37","author":"EA Gormley","year":"2010","unstructured":"Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am. 2010;37:601\u20137.","journal-title":"Urol Clin North Am"},{"key":"411_CR3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/00002060-200112000-00008","volume":"80","author":"BL Hicken","year":"2001","unstructured":"Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil. 2001;80:916\u201322.","journal-title":"Am J Phys Med Rehabil"},{"key":"411_CR4","unstructured":"Blok B, Pannek J, Castro-Diaz D, Del Popolo G, Groen J, Hamid R et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018."},{"issue":"3 Pt 1","key":"411_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, St\u00f6hrer G, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum toxin-A for treating detrusor hyperreflexia in spinal cord injured patientpt 1s: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1):692\u20137.","journal-title":"J Urol"},{"key":"411_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1586\/ern.12.61","volume":"12","author":"A Goessaert","year":"2012","unstructured":"Goessaert A, Everaert K. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. Exp Rev Neurother. 2012;12:763\u201375.","journal-title":"Exp Rev Neurother"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/00365590410015867","volume":"38","author":"P Bagi","year":"2004","unstructured":"Bagi P, Biering-S\u00f8rensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004;38:495\u20138.","journal-title":"Scand J Urol Nephrol"},{"key":"411_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1179\/107902611X13186000420242","volume":"34","author":"SC Kirshblum","year":"2011","unstructured":"Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, et al. Reference for the 2011 revision of the international standards for neurological classification of spinal cord injury. J Spinal Cord Med. 2011;34:547\u201354.","journal-title":"J Spinal Cord Med"},{"key":"411_CR9","first-page":"179","volume":"7","author":"HL Frankel","year":"1969","unstructured":"Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Paraplegia 1969;7:179\u201392.","journal-title":"Paraplegia"},{"key":"411_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sc.2017.59","volume":"55","author":"F Biering-S\u00f8rensen","year":"2017","unstructured":"Biering-S\u00f8rensen F, DeVivo MJ, Charlifue S, Chen Y, New PW, Noonan V, et al. International Spinal Cord Injury Core Data Set (version 2.0)\u2014including standardization of reporting. Spinal Cord 2017;55:759\u201364.","journal-title":"Spinal Cord"},{"key":"411_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37\u201349.","journal-title":"Urology"},{"key":"411_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742\u201350.","journal-title":"Eur Urol"},{"key":"411_CR13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131\u20139.","journal-title":"J Urol"},{"key":"411_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","volume":"111","author":"A Mohee","year":"2013","unstructured":"Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013;111:106\u201313.","journal-title":"BJU Int"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.eururo.2016.03.052","volume":"70","author":"L Leitner","year":"2016","unstructured":"Leitner L, Guggenb\u00fchl-Roy S, Kn\u00fcpfer SC, Walter M, Schneider MP, Tornic J, et al. More than 15 years of experience with intradetrusor onabotulinumtoxina injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol 2016;70:522\u20138.","journal-title":"Eur Urol"},{"key":"411_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/nau.23352","volume":"37","author":"C Joussain","year":"2018","unstructured":"Joussain C, Popoff M, Ph\u00e9 V, Evan A, Bosset PO, Pottier S, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn 2018;37:799\u2013806.","journal-title":"Neurourol Urodyn"},{"key":"411_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/iju.12205","volume":"21","author":"R Veeratterapillay","year":"2014","unstructured":"Veeratterapillay R, Harding C, Teo L, Vesdev N, Abroaf A, Dorkin TJ, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol. 2014;21:175\u20138.","journal-title":"Int J Urol"},{"key":"411_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/nau.23196","volume":"36","author":"MS Rahnama\u2019i","year":"2017","unstructured":"Rahnama\u2019i MS, Marcelissen TAT, Brierley B, Schurch B, de Vries P. Long-term compliance and results of intravesical botulinum toxin A injections in male patients. Neurourol Urodyn 2017;36:1855\u20139.","journal-title":"Neurourol Urodyn"},{"key":"411_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/sj.sc.3102145","volume":"46","author":"F Biering-S\u00f8rensen","year":"2008","unstructured":"Biering-S\u00f8rensen F, Craggs M, Kennelly M, Schick E, Wyndaele JJ. International lower urinary tract function basic spinal cord injury data set. Spinal Cord 2008;46:325\u201330.","journal-title":"Spinal Cord"}],"container-title":["Spinal Cord"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41393-019-0411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41393-019-0411-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41393-019-0411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:34Z","timestamp":1684618714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41393-019-0411-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1038\/s41393-019-0411-0","relation":{},"ISSN":["1362-4393","1476-5624"],"issn-type":[{"value":"1362-4393","type":"print"},{"value":"1476-5624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Danish data protection agency and the Danish patient safety authority. We certify that all applicable institutional and governmental regulations concerning the ethical use of data originally collected for clinical purposes were followed during the course of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"NK and KPH have received travel grants from Contura. ME has received honoraria and travel grants from Contura. However, Contura had no involvement in the collection, analysis, interpretation, or write up of this paper. PB and FBS have no disclosures to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}